Mizuho downgraded shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a buy rating to a neutral rating in a research note released on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has $7.00 price objective on the stock, down from their previous price objective of $12.00.
A number of other equities research analysts also recently weighed in on the company. ValuEngine downgraded Endo International from a hold rating to a sell rating in a research report on Monday, April 2nd. Barclays set a $9.00 price objective on Endo International and gave the company a hold rating in a research report on Saturday, March 10th. BidaskClub raised Endo International from a strong sell rating to a sell rating in a research report on Tuesday, March 6th. BMO Capital Markets dropped their price objective on Endo International from $10.00 to $9.00 and set a market perform rating on the stock in a research report on Monday, March 5th. Finally, Gabelli downgraded Endo International from a buy rating to a hold rating in a research report on Wednesday, February 28th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $9.40.
ENDP opened at $5.49 on Wednesday. Endo International has a 12-month low of $5.27 and a 12-month high of $14.15. The company has a debt-to-equity ratio of 17.00, a quick ratio of 0.85 and a current ratio of 1.02. The firm has a market cap of $1,277.51, a PE ratio of 1.43 and a beta of 0.38.
Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.15. Endo International had a positive return on equity of 81.03% and a negative net margin of 58.68%. The business had revenue of $768.64 million for the quarter, compared to the consensus estimate of $762.29 million. During the same quarter in the prior year, the company earned $1.77 EPS. The business’s revenue was down 38.1% compared to the same quarter last year. equities analysts expect that Endo International will post 2.33 EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. UBS Asset Management Americas Inc. boosted its holdings in Endo International by 4.4% in the fourth quarter. UBS Asset Management Americas Inc. now owns 221,992 shares of the company’s stock worth $1,720,000 after acquiring an additional 9,438 shares in the last quarter. Paloma Partners Management Co purchased a new position in Endo International during the fourth quarter valued at approximately $122,000. Oakbrook Investments LLC purchased a new position in Endo International during the fourth quarter valued at approximately $133,000. Xact Kapitalforvaltning AB purchased a new position in Endo International during the fourth quarter valued at approximately $157,000. Finally, Hunter Associates Investment Management LLC increased its position in shares of Endo International by 53.7% in the fourth quarter. Hunter Associates Investment Management LLC now owns 67,150 shares of the company’s stock valued at $520,000 after buying an additional 23,450 shares in the last quarter. 94.72% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Endo International (ENDP) Downgraded to “Neutral” at Mizuho” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/endo-international-endp-downgraded-to-neutral-at-mizuho.html.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.